. 2018 Jul 25;62:10.29219/fnr.v62.1398. doi: 10.29219/fnr.v62.1398

Table 4.

Effects of pretreatment with FPLR on cell viability and AST, ALT, and LDH activities of BRL hepatocyte injured by CC1₄ ( $\bar{X}$ ± SD, n = 5)

Groups	Cell viability (%)	ALT (U/L)	AST (U/L)	LDH (U/L)
Normal control	92.66 ± 0.29^f	1.63 ± 0.15^a	4.33 ± 0.58^a	75.67 ± 2.08^a
CCl₄-treated	23.64 ± 1.34^a	3.23 ± 0.21^d	17.00 ± 1.73^d	161.00 ± 3.00^e
FPLR (0.2 mg/mL) + CCl₄	45.04 ± 2.91^b	2.87 ± 0.21^cd	15.67 ± 1.15^cd	148.00 ± 1.73^d
FPLR (0.4 mg/mL) + CCl₄	57.33 ± 2.09^c	2.47 ± 0.12^bc	13.67 ± 0.58^bc	143.33 ± 1.53^d
FPLR (0.8 mg/mL) + CCl₄	64.59 ± 0.77^d	2.10 ± 0.20^ab	12.67 ± 1.53^bc	133.67 ± 2.52^c
FPLR (1.6 mg/mL) + CCl4	70.39 ± 1.77^e	1.73 ± 0.21^a	12.00 ± 1.00^b	117.67 ± 0.58^b

Data are shown as mean values ± SD (n = 5). Values within a column with different letters indicate significant difference among different groups at p < 0.05.